Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.89 +0.07 (+0.39%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Summit SMMT Q3 2025 Earnings Call Transcript ↗
Summit SMMT Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗
 
Via Benzinga
News headline image
Why Wall Street Is Backing These 3 Comeback Stocks ↗
Via MarketBeat
News headline image
1 Monster Stock in the Making to Buy and Hold ↗
The company's prospects improve with every clinical win. 
Via The Motley Fool
News headline image
Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗
Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the odds, or is this stock a risky bet? 
Via The Motley Fool
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗
Via Stocktwits
News headline image
An Overview of Summit Therapeutics's Earnings ↗
 
Via Benzinga
Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’ ↗
Via Stocktwits
News headline image
What's Going On With Summit Therapeutics Stock On Monday? ↗
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025. 
Via Benzinga
News headline image
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck. 
Via Benzinga
News headline image
Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗
Summit Therapeutics reported a wider-than-expected Q3 2025 loss but is advancing its lead drug, ivonescimab, toward a key FDA submission. 
Via Chartmill
News headline image
Earnings Scheduled For October 20, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
1 Monster Stock in the Making to Buy and Hold ↗
This biotech company was relatively unknown a few years ago. 
Via The Motley Fool
News headline image
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence ↗
 
Via Benzinga
News headline image
Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio? ↗
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
News headline image
Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends ↗
Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly... 
Via Benzinga
News headline image
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a meme stock." 
Via Benzinga
News headline image
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio? ↗
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others. 
Via Benzinga
Topics Earnings
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗
 
Via Benzinga
News headline image
Is Summit Therapeutics a Buy, Sell, or Hold Now? ↗
Western results for ivonescimab aren't lining up with the huge survival benefit measured in China. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Moves Higher; Robinhood Shares Jump ↗
 
Via Benzinga
News headline image
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
News headline image
Top movers in Monday's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences ↗
Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds. 
Via Benzinga
News headline image
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.